The historical data trend for Pharming Group's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PHAR vs VRTX, REGN, ALNY: Buyback Yield % Comparison
For the Biotechnology subindustry, Pharming Group's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharming Group Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharming Group's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Pharming Group's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharming Group (PHAR) has a Buyback Yield % of 0.00 as of Jul. 05, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Pharming Group and its competitors. According to the industry distribution chart, Pharming Group ranks #999999 out of 741 companies in the Biotechnology industry.
Is Pharming Group's Buyback Yield % too high?
Pharming Group's current Buyback Yield % is 0.00. Based on the distribution chart, Pharming Group ranks #999999 out of 741 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Pharming Group has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pharming Group's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharming Group ranks #999999 out of 741 companies for Buyback Yield %. This places Pharming Group in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Pharming Group and its competitors. Pharming Group's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharming Group stock overvalued right now?
Based on GuruFocus' analysis, Pharming Group (PHAR) is currently considered Fairly Valued. The stock's GF Value™ is $14.25, compared to a current price of $13.77 — trading 3.4% below its estimated fair value. The current Buyback Yield % is 0.00. Pharming Group's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Pharming Group (PHAR), the current Buyback Yield % is 0.00 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharming Group (PHAR) Overvalued in 2026?
Based on GuruFocus' analysis, Pharming Group stock appears to be undervalued.
The current stock price of $13.77 is trading 3.4% below its estimated GF Value™ of $14.25.
GuruFocus considers Pharming Group to be Fairly Valued.
Key valuation signals for PHAR:
Buyback Yield %: 0.00
GF Value™: $14.25 vs. price of $13.77 (3.4% below fair value)
No single metric tells the full story. See the PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
77GF Score
Get the complete analysis for PHAR
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHAR has been successfully added to your 
